12.06.2013 - Norway’s cancer radiotherapy specialist Algeta has signed an agreement with Australian antibody developer Avipep Pty Ltd.
Under the terms of the agreement, the Algeta ASA will evaluate a conjugate that couples the Oslo-based company’s alpha-emitter thorium-227 to Avipep’s Avibody, which targets a number of different solid tumour types. The thorium payload, which triggers DNA double-strand breaks that lead to cell death, have been shown to be highly localised, minimising off-target effects. Algeta has coupled the radionuclide to different cancer-targeting molecules such as Her2 and PDGFRβ.
Avipep will provide access to one of its proprietary Avibodies, which the company uses for targeting and labelling tumour cells. Algeta will provide access to chelation and conjugation technologies, as well as to its alpha particle-emitting payload thorium-227. Both companies will contribute financially to the collaboration, which is expected to last for up to one year initially with the option for further cooperation thereafter. No further terms have been disclosed. Algeta runs already collaborations with Genzyme and Affibody AB to develop Targeted Thorium Conjugates (TTC). After having brought its alpha-emitter radium-223 dichloride to the market, the company now seeks to evaluate targeted approaches of its technology. In contrast to cytotoxic payloads, TTC’s offer the advantage of not being subject to drug resistance.
23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.
15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.
11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.